LIPSTECH

The world's first reusable and connected saliva-based solution for glucose and metabolic health monitoring

Market Shift : CGM business explode after reimbursement of T1-2 insulino dependent around 2020 , but not because of easier dosing insulin but mainly because users with CGM can learn on adjusting food / excercise and this impact down their HbA1C reducing Diabetes risk . However 2025-dennis study showed 83% do not use CGM mainly because of cost, and dislike BGM because of pain, knowing 75% of diabetics are T2 light non reimbursed : this create huge frustration and T2 light market opportunity for a SIMPLE, PAINLESS & CHEAP glucose monitor
Team : we are a small team of diabetes experts (incl biochemist Phd) following 10 years of microneedle CGM-smartwatch, sold to WITHINGS in 2023
First‑in‑class innovation: We are developing the world’s first reusable, non‑invasive saliva biosensing platform for accurate glucose monitoring, with a pipeline expanding to lactate, uric acid, cortisol, and amino acids. Painless, cheap, discreet, natural & simple, reusable 60 times, sustainable
Massive unmet need: Current glucose monitoring tools are invasive,and stigmatized , and either painful (BGM) or expensive (CGM). Our solution eliminates those barriers, driving higher adherence and better outcomes, with a focus on education & motivation with simple lipstick usage & weekly feedback on A1C value/trend to reflect the week efforts, bringing strong motivation to keep the track to get below 7% A1C
Scalable market impact: Diabetes care alone represents a $12B+ global monitoring market. 75% of diabetics are non insulino dependent , a silent pathology population, an abandonned market (non reimbursed , not seen by diabetologist), and with extra adjacent opportunities in sports medicine, stress diagnostics, and preventive health. Our survey on 300 USA T2 light confirmed 36% are ready to buy out of pocket, mainly T2D overweight & stressed by glucose control
Regulatory and technical expertise: Our team combines deep medical device development experience with ISO 13485 regulatory alignment, ensuring a clear path to CE marking and FDA approval , validated by expert such as VCLS and Qsub FDA meeting confirming step 1 a wellness device & step 2 a 510K GRM / BGM devices, followed by reimbursement strategy (with clinical trial impact on A1C planed in 2027)
Accessible and affordable design: Leveraging lipstick (Chapstick) form-factor and focusing on reusability and simplicity, we will deliver a product that is not only clinically relevant but also commercially viable for broad adoption, being painless & inexpensive (39$ with a reusable consumable of 60 tests with limit of 60 days)
Technology: A reusable glucose absorbent pad foam painlessly collects saliva from the inside of the lip and transfers it to a CGM type enzyme sensor located in the cap, with nanomaterial sub ayer to enhance the signal, glucose being ≈100 times less concentrate in saliva than in blood. The test results are instantly delivered to your phone and the absorbent pad is automatically sterilized using UV light for safe and frequent use.
Clinical results : an official clinical trial with FDA qualified CRO in india demonstrated on 180 T2D under oral pill, a 98% accuracy vs BGM/CGM & no safety issue with 85% of patients prefering the product vs BGM or CGM
Vision for long‑term wellbeing: We empower individuals to take control of their metabolic health with clear, actionable feedback—reducing burden and improving quality of life
Go to market : launch product in 2027 for wellness version & 2028 for medical version , USA first, then EU / CHINA
Vision : becoming the world leader on glucose monitoring in the T2D light segment, and expanded to larger metabolism control

Fundraise Details

This section is only visible to registered investors. Log in or register as an accredited investor to view.

Ready to Ask For Funding for your company?

Post a Funding Request

LIPSTECH

Fundraise Details

Key Facts